Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF 25.62
+0.06 (0.23%)
Jan 30, 2026, 5:30 PM CET
Kuros Biosciences AG Revenue
Kuros Biosciences AG had revenue of 63.48M CHF in the half year ending June 30, 2025, with 393.39% growth. This brings the company's revenue in the last twelve months to 103.35M, up 129.81% year-over-year. In the year 2024, Kuros Biosciences AG had annual revenue of 75.56M with 125.11% growth.
Revenue (ttm)
103.35M
Revenue Growth
+129.81%
P/S Ratio
9.71
Revenue / Employee
654.12K
Employees
158
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75.56M | 41.99M | 125.11% |
| Dec 31, 2023 | 33.56M | 15.58M | 86.61% |
| Dec 31, 2022 | 17.99M | 4.17M | 30.19% |
| Dec 31, 2021 | 13.82M | 9.78M | 242.04% |
| Dec 31, 2020 | 4.04M | 1.48M | 57.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.95B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 3.73B |
| Aevis Victoria | 955.96M |
| Tecan Group AG | 906.60M |
| PolyPeptide Group AG | 344.49M |
| SKAN Group AG | 332.13M |
Kuros Biosciences AG News
- 3 months ago - Kuros 9-month Revenue Up 77%; Raises 2025 Sales Guidance - Nasdaq